Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus FLUOTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus FLUOTREX.
COR-OTICIN vs FLUOTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
The active metabolite of FLUOTREX, 5-fluorouracil (5-FU), inhibits thymidylate synthase, leading to depletion of thymidine triphosphate and inhibition of DNA synthesis. Additionally, it incorporates into RNA, disrupting RNA function.
1-2 drops in each affected ear twice daily for 7 days.
20 mg/m2 intramuscularly once weekly, not to exceed 30 mg/m2 per week.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10-15 hours, necessitating dose adjustment.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal excretion as unchanged drug (approximately 60-70% of administered dose), with the remainder eliminated via biliary/fecal routes (20-30%) and minor metabolic clearance.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid